About Mitochondrial chaperone BCS1
Mitochondrial chaperone BCS1 (BCS1L) is a protein
from Homo sapiens identified by UniProt accession
Q9Y276, 419 residues long.
MolForge cross-references it against 0 known binders and
136 disease associations.
Target properties
| Protein name | Mitochondrial chaperone BCS1 |
| UniProt accession | Q9Y276 |
| Gene | BCS1L |
| Organism | Homo sapiens |
| Length | 419 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (136)
Diseases linked to this target (Open Targets).
- GRACILE syndrome · score 0.81
- Isolated CoQ-cytochrome C reductase deficiency · score 0.79
- Björnstad syndrome · score 0.77
- Bjornstad syndrome · score 0.77
- mitochondrial complex III deficiency nuclear type 1 · score 0.76
- Leigh syndrome · score 0.70
- Renal tubulopathy - encephalopathy - liver failure · score 0.67
- neurodegenerative disease · score 0.55
- genetic disorder · score 0.50
- Microcephaly · score 0.48
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9Y276-F1 | alphafold | PREDICTED | 86.96 | — |
Amino-acid sequence (419 residues)
MPLSDFILAL KDNPYFGAGF GLVGVGTALA LARKGVQLGL VAFRRHYMIT LEVPARDRSY AWLLSWLTRH STRTQHLSVE TSYLQHESGR ISTKFEFVPS PGNHFIWYRG KWIRVERSRE MQMIDLQTGT PWESVTFTAL GTDRKVFFNI LEEARELALQ QEEGKTVMYT AVGSEWRPFG YPRRRRPLNS VVLQQGLADR IVRDVQEFID NPKWYTDRGI PYRRGYLLYG PPGCGKSSFI TALAGELEHS ICLLSLTDSS LSDDRLNHLL SVAPQQSLVL LEDVDAAFLS RDLAVENPVK YQGLGRLTFS GLLNALDGVA STEARIVFMT TNHVDRLDPA LIRPGRVDLK EYVGYCSHWQ LTQMFQRFYP GQAPSLAENF AEHVLRATNQ ISPAQVQGYF MLYKNDPVGA IHNAESLRR
Explore Mitochondrial chaperone BCS1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets